论文信息 - Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. - 字舞流文

Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

S. Durston | G. McClelland | M. Aitken | N. D. Wood | S. Sharp | S. Harris

[1] J. Bishop,et al. Ro 32‐3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo , 1997, British journal of pharmacology.

[2] G. Murphy,et al. Matrix metalloproteinases and their inhibitors. , 1995, Acta orthopaedica Scandinavica. Supplementum.

[3] C. Brinckerhoff,et al. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? , 1994, Arthritis and rheumatism.

[4] P. Brooks. Clinical management of rheumatoid arthritis , 1993, The Lancet.

[5] F. Epstein,et al. Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[6] R W Jubb,et al. The breakdown of collagen by chondrocytes , 1980, The Journal of pathology.

[7] M. K. Kumar,et al. Molecular basis of new approaches to the therapy of rheumatoid arthritis. , 1991, Molecular aspects of medicine.

[8] T. Hardingham,et al. Chondrocyte responses in cartilage and in experimental osteoarthritis. , 1991, British Journal of Rheumatology.

[9] M. Stephenson,et al. Modulation of matrix synthesis and degradation in joint inflammation , 1988 .

[10] N. Borkakoti,et al. Collagenase inhibitors: their design and potential therapeutic use. , 1987, Journal of enzyme inhibition.